KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMY) Other Non-Current Liabilities (2016 - 2025)

Historic Other Non-Current Liabilities for Bristol Myers Squibb (BMY) over the last 17 years, with Q3 2025 value amounting to $5.5 billion.

  • Bristol Myers Squibb's Other Non-Current Liabilities rose 1546.11% to $5.5 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.5 billion, marking a year-over-year increase of 1546.11%. This contributed to the annual value of $4.5 billion for FY2024, which is 3040.02% down from last year.
  • According to the latest figures from Q3 2025, Bristol Myers Squibb's Other Non-Current Liabilities is $5.5 billion, which was up 1546.11% from $4.9 billion recorded in Q2 2025.
  • Bristol Myers Squibb's 5-year Other Non-Current Liabilities high stood at $7.7 billion for Q1 2021, and its period low was $4.5 billion during Q4 2024.
  • Moreover, its 5-year median value for Other Non-Current Liabilities was $6.6 billion (2022), whereas its average is $6.2 billion.
  • Data for Bristol Myers Squibb's Other Non-Current Liabilities shows a peak YoY increase of 1546.11% (in 2025) and a maximum YoY decrease of 3349.67% (in 2025) over the last 5 years.
  • Over the past 5 years, Bristol Myers Squibb's Other Non-Current Liabilities (Quarter) stood at $7.3 billion in 2021, then dropped by 10.14% to $6.6 billion in 2022, then fell by 2.56% to $6.4 billion in 2023, then plummeted by 30.4% to $4.5 billion in 2024, then grew by 22.15% to $5.5 billion in 2025.
  • Its Other Non-Current Liabilities was $5.5 billion in Q3 2025, compared to $4.9 billion in Q2 2025 and $4.5 billion in Q1 2025.